—Suspension of reimbursement: Don’t see evidence of this. Do...

—Suspension of reimbursement: Don’t see evidence of this. Do you?

—Missed bank covenants: Not the end of the world as long as the lender maintains the great relationship with Avita, assuming it happens again. Last quarter equated to a waiver despite prior fear-mongering regarding what happens if a covenant is missed.

—Missed sales/income guidance: Guidance misses have happened, but keep in mind that Avita is in full rollout mode now with Cohealyx and Recell Go mini alongside. Also, guidance reached for the moon and almost got there.

—Deterioration of balance sheet: Obviously. There are no profits yet; those are not expected until Q4.

—Promises need to be delivered. I agree. But keep in mind that management has not reached market saturation yet, and there’s still tons to penetrate of the $3.5 billion TAM. It’s probably really difficult to make accurate forecasts while in a rollout phase that involves seeking adoption by hospitals/surgeons. Overall, revenues are expected to keep going up YoY while expenses come down. Then, the balance sheet will eventually start growing once reaching profitability. Just my thoughts.

I find it important to note that Cohealyx builds upon established biotech science.